More delays is what the new wave of prescription drug affordability boards in 11 states are promising.
James K. Glassman
Advertisement
Articles by James K. Glassman
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Medical Economics
1
CMS wants to know if the CPT coding monopoly is hurting patient care
2
Inside CMS's push to rebalance Medicare payments toward primary care
3
Latest on the cyclospora outbreak; first oral PCSK9 inhibitor approved; AHA update: how much coffee is heart-safe? — Morning Medical Update
4
Why ChatGPT favors hospitals over independent practices
5